KR870004703A - 비-스테로이드성 소염제의 국소투여에 의한 수술후 유착증발생 억제방법 - Google Patents

비-스테로이드성 소염제의 국소투여에 의한 수술후 유착증발생 억제방법 Download PDF

Info

Publication number
KR870004703A
KR870004703A KR860010031A KR860010031A KR870004703A KR 870004703 A KR870004703 A KR 870004703A KR 860010031 A KR860010031 A KR 860010031A KR 860010031 A KR860010031 A KR 860010031A KR 870004703 A KR870004703 A KR 870004703A
Authority
KR
South Korea
Prior art keywords
active ingredient
composition
ester
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
KR860010031A
Other languages
English (en)
Other versions
KR940006321B1 (ko
Inventor
디. 쉬필드 워렌
비. 죤스 더글라스
더블류.셀라비 셀라비
에스. 디저르가 저어
이 엘. 리춰 레로
Original Assignee
로버트 엘. 미니어
에티콘 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 엘. 미니어, 에티콘 인코포레이티드 filed Critical 로버트 엘. 미니어
Publication of KR870004703A publication Critical patent/KR870004703A/ko
Application granted granted Critical
Publication of KR940006321B1 publication Critical patent/KR940006321B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

비-스테로이드성 소염제의 국소투여에 의한 수술후 유착증발생 억제방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (27)

  1. 활성성분으로서 비-스테로이드성 소염제를 함유하는 무균 조성물 유효량을, 수술후의 유착증 발생을 억제하기에 충분한 기간동안 수술외 상부위에 국소투여함을 특징으로하여 포유동물에 있어서의 수술후의 유착증발생을 억제하는 방법.
  2. 제1항에 있어서, 활성성분이 이부프로펜 또는 이의 약학적으로 허용되는 염 또는 에스테르인 방법.
  3. 제1항에 있어서, 활성성분이 수프로펜 또는 이의 약학적으로 허용되는 염 또는 에스테르인 방법.
  4. 제1항에 있어서, 활성성분이 톨메틴 또는 이의 약학적으로 허용되는 염 또는 에스테르인 방법.
  5. 제1항에 있어서, 활성성분이 언급된 기간에 걸쳐 유효량으로 언급된 활성성분을 방출하는 방출-조절담체중에 함유되는 방법.
  6. 제5항에 있어서, 담체가 인지질인 방법.
  7. 제6항에 있어서, 인지질이 인지질 베시클(vesicle)인 방법.
  8. 제7항에 있어서, 인지질 베시클이 멀티라멜라(multilamellar)베시클인 방법.
  9. 제8항에 있어서, 베시클이 약 1 내지 약 10마이크론의 크기를 갖는 방법.
  10. 제8항에 있어서, 베시클이 지방산 잔기가 단일 지방산으로부터 유도되는 포스페이티딜 콜린으로 이루어진 방법.
  11. 제8항에 있어서, 베시클이 포스페이티딜 콜린과 콜레스테롤 과의 혼합물로 이루어진 방법.
  12. 제5항에 있어서, 담체가 흡수성 중합체인 방법.
  13. 제12항에 있어서, 흡수성 중합체가 락트산, 글리콜산, 이들의 환식 이량체 에스테르 또는 p-디옥사논의 호모폴리머 또는 공중합체인 방법.
  14. 제13항에 있어서, 중합체가 마이크로캡슐 형태인 방법.
  15. 제1항에 있어서, 언급된 기간이 약 1 내지 7일인 방법.
  16. 제14항에 있어서, 마이크론캡슐이, 수술외상 부위에 점착하기 위한 마이크론캡슐의 능력을 증강시키기에 충분한 양으로 렉시틴을 함유하는 방법.
  17. 제1항에 있어서, 활성성분이, 계면활성제를 함유하는 수성조성물중에 함유되는 방법.
  18. 제17항에 있어서, 수성 조성물이 에톡실화된 솔비탄 모노-올레이트의 수용액으로 이루어진 방법.
  19. 제1항에 있어서, 조성물이 단일용량으로 투여되며, 조성물중의 활성성분의 농도가 약 0.025 내지 5mg/ml인 방법.
  20. 제1항에 있어서, 조성물이 언급된 기간에 걸쳐 연속적으로 투여되며, 조성물중의 활성성분의 농도가 약 0.01 내지 10mg/ml인 방법.
  21. 계면활성제 및 비-스테로이드성 소염제를 함유하는 무균 수성 조성물.
  22. 제21항에 있어서, 약제가 이부프로펜, 수프로펜, 톨메틴 또는 이들의 약학적으로 허용되는 염 또는 에스테르인 무균 조성물.
  23. 비-스테로이드성 소염제를 함유하는 인지질 베시클로 이루어진 무균 조성물.
  24. 제23항에 있어서, 약제가 이부프로펜, 톨메틴, 수프로펜, 또는 이들의 약학적으로 허용되는 염 또는 에스테르인 방법.
  25. 비-스테로이드성 소염제를 함유하는 흡수성 중합체 마이크로캡슐로 이루어진 무균 조성물.
  26. 제25항에 있어서, 중합체가 락티드, 글리콜리드 또는 p-디옥사논의 호로폴리머 또는 공중합체인 조성물.
  27. 제26항에 있어서, 약제가 이부프로펜, 수프로펜, 톨메틴 또는 이들의 약학적으로 허용되는 염 또는 에스테르인 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860010031A 1985-11-27 1986-11-27 수출후의 유착증 발생을 억제하기 위한 국소투여용 비-스테로이드성 소염제 함유 담체의 제조방법 KR940006321B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80254585A 1985-11-27 1985-11-27
US802,545 1985-11-27
US802545 1985-11-27
US90012286A 1986-08-25 1986-08-25
US900122 1986-08-25
US900,122 1986-08-25

Publications (2)

Publication Number Publication Date
KR870004703A true KR870004703A (ko) 1987-06-01
KR940006321B1 KR940006321B1 (ko) 1994-07-16

Family

ID=27122463

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860010031A KR940006321B1 (ko) 1985-11-27 1986-11-27 수출후의 유착증 발생을 억제하기 위한 국소투여용 비-스테로이드성 소염제 함유 담체의 제조방법

Country Status (7)

Country Link
EP (1) EP0225162B1 (ko)
JP (1) JPH0798755B2 (ko)
KR (1) KR940006321B1 (ko)
AU (1) AU587299B2 (ko)
DE (1) DE3683606D1 (ko)
GR (1) GR3003915T3 (ko)
YU (1) YU46032B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
GB8701392D0 (en) * 1987-01-22 1987-02-25 Boots Co Plc Therapeutic agents
WO1991012026A1 (en) * 1990-02-14 1991-08-22 Macnaught Pty Limited Means of reducing surgical adhesions
WO1992009268A1 (en) * 1990-12-03 1992-06-11 Vestar, Inc. Prevention of synovial adhesions
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
GR1003359B (el) * 1998-12-24 2000-04-10 �.�. ����������� �.�.�.�. Λιποσωμιακο νιφλουμικο οξυ - νεο διαδερμικο αντιφλεγμονωδες φαρμακο [κεφαλη ψαροτουφεκου
JP2003519651A (ja) * 2000-01-14 2003-06-24 ブラウン ユニバーシティ リサーチ ファウンデーション 微紛化凍結乾燥粒子
US7029700B2 (en) 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
JP4768440B2 (ja) * 2003-03-06 2011-09-07 セルミド リミテッド 開腹手術後の癒着の予防剤
US9066912B2 (en) * 2003-11-17 2015-06-30 Ethicon, Inc. Drug-enhanced adhesion prevention
US20050106230A1 (en) * 2003-11-17 2005-05-19 Young Janel E. Drug-enhanced adhesion prevention
DE102008005172A1 (de) * 2008-01-19 2009-07-23 Mike Ehrlich Pharmazeutische Zusammensetzung zur Verhinderung von post-operativen Adhäsionen
ES2330295B1 (es) 2008-06-06 2010-09-23 Laboratorios Alcala Farma, Sl Formulacion topica de ibuprofeno.
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4346108A (en) * 1981-06-22 1982-08-24 The Upjohn Manufacturing Company M Method for preventing adhesion formation
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents

Also Published As

Publication number Publication date
DE3683606D1 (de) 1992-03-05
EP0225162A3 (en) 1987-11-19
AU587299B2 (en) 1989-08-10
AU6570986A (en) 1987-06-04
EP0225162A2 (en) 1987-06-10
EP0225162B1 (en) 1992-01-22
JPH0798755B2 (ja) 1995-10-25
YU202886A (en) 1988-06-30
GR3003915T3 (ko) 1993-03-16
KR940006321B1 (ko) 1994-07-16
YU46032B (sh) 1992-12-21
JPS62155223A (ja) 1987-07-10

Similar Documents

Publication Publication Date Title
KR870004703A (ko) 비-스테로이드성 소염제의 국소투여에 의한 수술후 유착증발생 억제방법
Gesztes et al. Topical anesthesia of the skin by liposome-encapsulated tetracaine
US6299902B1 (en) Enhanced transdermal anesthesia of local anesthetic agents
US4637930A (en) Transdermal formulation of nicardipine hydrochloride
JP2660839B2 (ja) 局所塗布用浸透促進製薬組成物
ES2343767T3 (es) Composiciones anestesicas liposomicas de liberacion sostenida.
AU706541B2 (en) Formulations and methods for providing prolonged local anesthesia
US20030072814A1 (en) Topical pharmaceutical composition for the treatment of warts
CA2273183A1 (en) Treatment of equine laminitis
US6821523B2 (en) Topical administration of pharmacologically active bases in the treatment of warts
WO2004000360A1 (en) Use of topical pharmaceutical compositions comprising an active agent and permeation-enhancing base for the manufacture of a medicament to treat various forms of inflammatory dermatosis
AU8644291A (en) Drug delivery vehicles suspended in nonaqueous perfluorinated carrier
RU2001129362A (ru) Композиция, включающая ундеканоат тестостерона и касторовое масло
EP1296679B1 (de) Dermales therapeutisches system enthaltend nichtsteroidale antiphlogistika mit selektiver cox-2-hemmung
US5747069A (en) Percutaneously absorbable preparation
CA1297791C (en) Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator
US5965623A (en) Anti-glucocorticoid drug
WO2023137405A2 (en) Ultraflexible liposomes in gel formulation
UA75345C2 (en) Pharmaceutical composition for topical use intended for treating sebaceous gland disorders and methods of treating acnes using this composition
BE881238A (nl) Farmaceutisch preparaat en werkwijze ter bereiding daarvan
US5248674A (en) Percutaneous administration of 3'-azide'-deoxythymidine
KR100552649B1 (ko) 펠비낙 함유 소염진통용 플라스터
KR20050047198A (ko) 피록시캄 함유 소염진통용 플라스터
US5622942A (en) Percutaneous absorptive anesthetic
BE1018506A3 (nl) Samenstelling van een hydrocortisone, zijn derivaten, metabolieten, prodrugs of mengsels daarvan houdende liposomale gel en het gebruik ervan.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060711

Year of fee payment: 13

EXPY Expiration of term